GC155 Is Blood Transfusion Absolutely Required In Patient Management Nowadays
Blood transfusion remains essential in specific clinical scenarios such as massive hemorrhage, severe anemia, and critical coagulopathies, though modern alternatives like cell salvage, erythropoietin, and restrictive transfusion strategies have significantly reduced its absolute necessity.
Is Blood Transfusion Absolutely Required in Patient Management Nowadays?
The Big Idea: Blood transfusion is a life-saving but imperfect therapy. It is not always necessary, carries real risks, and faces supply constraints. The modern paradigm—Patient Blood Management (PBM)—shifts the focus from reflexive transfusion to optimising the patient's own haematopoiesis, minimising blood loss, and safely managing anaemia according to physiology and context. The answer to the title question is: transfusion is absolutely required in some scenarios, but can and should be avoided or minimised in many others.
Learning Objectives (from the lecture slides) [1]:
- Why does one need blood transfusion during treatment?
- Is current blood transfusion safe enough?
- What can I do if I don't want blood transfusion?
- How and what can a doctor advise on blood transfusion?
Read the Pathway Component by Component
The haemoglobin threshold applies to red cells, not to platelets, plasma or cryoprecipitate. “One unit, then reassess” applies to a stable adult without active bleeding; it is not a rule for major haemorrhage. Conversely, haemodynamic stability does not make severe symptomatic anaemia safe to ignore. [14][15]
Core Concepts and Mechanisms
Typical indications: (a) anaemia to a degree with moderate to serious symptoms, (b) active blood loss in trauma or surgical operation, (c) leukaemia, thalassaemia major, other causes of bone marrow failure. [1]
From first principles:
- Red blood cells carry oxygen. When Hb drops acutely, oxygen delivery to tissues falls → tissue hypoxia → organ dysfunction → death.
- Platelets form the primary haemostatic plug. When platelet count is critically low (or function impaired), uncontrolled bleeding ensues.
- Coagulation factors (in plasma) amplify and stabilise the clot. Deficiency → coagulopathic bleeding.
- In marrow failure or ineffective erythropoiesis (for example, aplastic anaemia, some leukaemias and transfusion-dependent thalassaemia), transfusion can be essential supportive therapy. It may be a temporary bridge or a long-term programme depending on the disease and definitive treatment options.
Why blood transfusion is often needed: [1]
- Surgical operation — blood loss can range from minimal to massive depending on site and patient condition
- Bone marrow failure, leukaemia, thalassaemia — haematopoiesis fails → transfusion alleviates anaemia symptoms and bleeding. Can be temporary or permanent.
- Anaemia in elderly with co-morbidities — less likelihood of self-recovery
Blood transfusion should not always be given! [1]
- Many patients undergo treatment not in life-threatening conditions. They may come in for elective operation.
- There are alternatives to enhance erythropoiesis or correct the underlying situation.
- Doctors can have drugs and skills to reduce, minimise, control or stop bleeding.
- Bedside tools (POCT) to monitor coagulopathy and guide specific treatment.
Wrong Decisions for Transfusion — High Yield
Wrong decision for transfusion: [1]
- "Good for weakness and malaise" — Transfusion is NOT a tonic. It does not treat fatigue unless it is caused by significant anaemia.
- "More are better" — Each unit exposes the patient to additional risk. The modern approach is single unit transfusion and reassess.
4 Dimensions to consider: Adequacy, Quality, Safety, Outcome [1]
| Dimension | Key Points |
|---|---|
| Adequacy | Refers to common blood products (red cells, platelets, plasma) of common blood groups. Supply ≠ turning on a tap. Short shelf-life products (e.g. platelets: 5 days at 20–24°C) are especially vulnerable to shortage. |
| Quality | Affected by donor medication/diet/health, processing procedures, storage and handling at hospital blood bank and wards. |
| Safety | Blood is a biological product. Screening is comprehensive but not exhaustive because of window periods and emerging pathogens. Recipient vulnerability varies; transfusion does not itself mean that every recipient is immunocompromised. |
| Outcome | Balance risks against the component-specific benefit: red cells improve oxygen-carrying capacity, while platelets/plasma/fibrinogen may support haemostasis when an appropriate deficit exists. Transfusion does not treat the underlying cause, so recovery still depends on definitive disease and bleeding control. |
Blood Supply Challenges
Interpret the Figures in Their Lecture Context
The donation and screening figures below are a lecture-era snapshot, with the collection graphs extending to 2022. They explain the supply problem but are not live Blood Transfusion Service policy or current residual-risk estimates.
For every 1,000 Hong Kong citizens, only 30 participate in blood donation — and this is SHRINKING. [1]
- Ageing population → increasing demand
- Fewer young donors → new young donors (< 25) have declined dramatically since 2010 [1]
- COVID-19 pandemic → disrupted donation drives
- Public health factors → low Hb and high prevalence of iron deficiency in the general (donor) population [1]
- Clinical control of blood usage lags behind Western countries [1]
- School blood drives have fallen from 406 drives/year (2005-06) to 129 (2021-22) [1]
BTS (Blood Transfusion Service) is responsible for collection, processing and testing. BTS supplies blood to hospital blood banks. Blood supply is driven by clinical demand. [1]
- The 2009–2022 collection-versus-demand chart shows a narrow operating buffer, not an unlimited reserve. Both collection and use peaked around 2015 and were substantially lower by 2022; the pandemic period should not be extrapolated as a new steady state. [1]
- About 10.9% of whole-blood/red-cell demand in the 2014–2022 figure came from non-HA hospitals; most demand was within HA hospitals. [1]
- Donors younger than 25 fell from roughly 34,000 in 2011 to about 7,000 in 2022. This and the collapse in school drives explain why the lecture treats recruitment of young donors as a structural supply problem. [1]
- The supply–demand balance diagram adds an operational point: requests depend on the patient's group, component, quantity and timing. Rare groups, red-cell antibodies and special processing can delay availability, so communicate with the blood bank early rather than ordering speculative units. [1]
| Product | Storage | Shelf Life | Notes |
|---|---|---|---|
| Packed red cells | 2–6°C | 42 days | Current HK BTS specification [20] |
| Whole blood | 2–6°C | 28–35 days | Most donations are separated into components [20] |
| Platelet concentrates | 20–24°C with continuous agitation | 5 days | Short life = recurrent supply pressure [20] |
| Frozen plasma | Below −30°C | 365 days | Thawing and post-thaw expiry follow the hospital blood-bank protocol [20] |
| Cryoprecipitate | Below −30°C | 365 days | Concentrated source of fibrinogen, factor VIII and factor XIII [20] |
Current HK BTS public information confirms the following workflow: [19][20]
- Immunohaematology: ABO and Rh(D) typing plus irregular red-cell antibody screening.
- Routine infectious markers: HIV antigen/antibodies/RNA; HBsAg/HBV DNA; anti-HCV/HCV RNA; HEV RNA; anti-HTLV I/II; and syphilis antibody.
- Platelets: bacterial surveillance is performed on every platelet concentrate before release.
- Selected donations: CMV antibody testing supplies CMV-negative components when clinically indicated.
The slide also lists “Zika by NAT” as targeted testing, but this is not on the current BTS public list of routine or selected tests. Testing capability in a reference setting is not the same as universal donor screening; check current BTS policy during an outbreak. [1][19]
Why both serology AND NAT? Serology detects antibodies/antigens but misses the "window period" (time between infection and detectable markers). NAT detects viral nucleic acid directly, shortening the window period dramatically.
Transfusion Risks
Residual risk reported in the lecture slides and the BTS public page: [1][19]
Pathogen Public HK estimate Lecture window period HIV Approximately 1 in 3.4 million 5.9 days Hepatitis C Less than 1 in 10 million 2.6 days Hepatitis B Approximately 1 in 126,000 15.1 days
Do Not Present Historical Estimates as Live Risk
The BTS webpage explicitly says these estimates use 2016/17 donor epidemiology. Among the three viruses shown, its estimated residual risk was highest for HBV, plausibly reflecting local prevalence, the longer NAT window and occult low-level infection. The slide's crossed-out HIV figures and replacement “>1 in 10 million” do not match the current public BTS figure of about 1 in 3.4 million. Use these numbers for interpreting the lecture figure—not as a personalised, real-time consent estimate. [1][19]
The slide's emerging-pathogen message: [1]
- Malaria and dengue assays may exist, but they are not listed as universal HK donation screening.
- The historical vCJD travel restriction is shown as lifted.
- Zika and Japanese encephalitis illustrate why epidemiological surveillance and donor deferral remain necessary even when routine testing is unavailable.
The lecture specifically notes a transfusion-transmitted Japanese Encephalitis case on 21/07/2017 in Hong Kong [1].
Non-infectious transfusion risks: [1]
First Response to a Suspected Acute Reaction
Stop the transfusion and do not simply slow it. Assess airway, breathing, circulation and vital signs; maintain IV access with compatible fluid, recheck patient/unit identity, notify the responsible clinician and blood bank, and investigate according to the local reaction protocol. Do not restart a unit after TACO, TRALI, suspected haemolysis, sepsis or anaphylaxis. [21]
| Reaction | Frequency | Key Features |
|---|---|---|
| Febrile non-haemolytic transfusion reaction (FNHTR) | Relatively common | Fever, chills, rigors. Exclude acute haemolysis and bacterial contamination before labelling it FNHTR. An antipyretic may be used after serious causes are excluded; restart only if local policy and the responsible clinician permit. [2][21] |
| Minor allergic reaction | Relatively common | Isolated urticaria or pruritus. Stop and assess because early anaphylaxis may initially look mild; an antihistamine and cautious restart are only appropriate after clinical review and local-protocol clearance. [2][21] |
| Haemolytic transfusion reaction | Rare but can be fatal | ABO mismatch → acute intravascular haemolysis → DIC, renal failure. Most commonly due to clerical/identification error. [1][2] |
| Transfusion-associated circulatory overload (TACO) | Often under-recognised | New/worsening respiratory distress and pulmonary oedema from circulatory overload, usually within 12 h; hypertension, positive fluid balance and response to diuretics support the diagnosis. Stop transfusion, sit upright, give oxygen and diuretic/cardiac-failure therapy as indicated. Prevent with the minimum effective dose and slower rate in high-risk patients. [21] |
| Transfusion-related acute lung injury (TRALI) | Rare | Acute hypoxaemia with bilateral non-cardiogenic pulmonary oedema during or within 6 h, without circulatory overload as the main explanation. Donor anti-HLA/HNA antibodies are one mechanism, not the only mechanism. Stop transfusion and provide supportive respiratory care; diuresis is not routine unless overload coexists. [2][21] |
| Transfusion-associated GvHD (TA-GvHD) | Very rare, usually fatal | Viable donor T lymphocytes engraft and attack recipient tissues. Prevent with irradiation of indicated cellular components; plasma and cryoprecipitate are not treated for this purpose. [1][23] |
| Post-transfusion purpura | Not seen locally [1] | Thrombocytopenia 5–10 days post-transfusion due to anti-platelet antibodies. |
Patient Blood Management (PBM)
PBM: A multidisciplinary, evidence-based approach to optimizing the care of patients who might need a blood transfusion. Aims to improve patient outcomes. Quite often, better outcomes can be achieved with reduction or avoidance of exposure to allogeneic blood. [1]
Modifying the Risk Factors: [1]
- Optimise red cell mass — Treat anaemia and iron deficiency pre-operatively
- Minimise blood loss and bleeding — Surgical technique, haemostatic drugs, POCT-guided coagulation management
- Harness and optimise physiological reserve of anaemia — Optimise cardiopulmonary function so the patient can tolerate lower Hb
The slide preceding the Western Australia study presents broad ranges reported across PBM programmes: transfusion use ↓10–95%, length of stay ↓16–33%, reoperation/readmission up to ↓43%, composite morbidity up to ↓41%, infection up to ↓80%, and cost ↓10–84%. These ranges come from heterogeneous programmes and should be read as an implementation overview—not as treatment-effect estimates for an individual patient. [1]
Western Australia Study (4 adult tertiary-care hospitals, 604,046 admissions, 2008–2014): [1]
Clinical Outcome Reduction Hospital length of stay ↓15% In-hospital mortality ↓28% Hospital-acquired infections ↓21% Heart attack or stroke ↓31%
Blood Product Reduction Red cells (units per 1000 admissions) 311 → 182 (↓41%) Plasma ↓47% Platelets ↓28% Product-related cost savings: AU $18.5M [1]
Association Is Not the Same as Causation
The Western Australia study was a retrospective health-system study across a six-year implementation period. It supports an association between PBM, reduced component use and improved outcomes, but secular changes and other co-interventions prevent attributing every outcome reduction to PBM alone. The stronger, current message is that WHO endorses PBM as a patient-centred framework addressing anaemia, iron deficiency, coagulopathy and blood loss while promoting clinically indicated transfusion. [18]
How Can Blood Transfusion Be Minimised?
| Factor | Details |
|---|---|
| Surgical factors | Operating site, procedure type, local haemostatic control, proximity to major vessels |
| Doctor's factors | Technical skill, confidence level, willingness to seek help |
| Patient's factors | Age, underlying medical illnesses (heart/lung disease), coagulation disorders, rare blood groups, presence of red cell antibodies |
| Others | Pre-surgical optimisation (very important!!) — diagnose and manage anaemia esp. iron deficiency; optimise cardiopulmonary reserve; pre-surgical autologous deposits; perioperative cell salvage; postoperative salvage |
Pre-surgical autologous deposits, perioperative deposits and salvage, postoperative salvage — still very uncommonly practised in Hong Kong. [1]
This is a lecture-era description, not a hierarchy of preferred modern practice. Current NICE guidance offers oral iron for perioperative iron-deficiency anaemia and reserves IV iron for intolerance/malabsorption/non-adherence, functional iron deficiency, or when the interval to surgery is too short for oral therapy. It recommends tranexamic acid for appropriate surgery and considers intra-operative cell salvage with tranexamic acid when very high blood loss is expected. Predeposit autologous donation is not a routine substitute for PBM. [15]
KWH O&G retrospective cohort: 114 women aged 16–54 with severe iron-deficiency anaemia from menorrhagia were given two 200 mg doses of IV iron sucrose plus oral iron: [1]
Parameter Pre-treatment Post-treatment Hb (g/dL) 7.1 ± 0.7 10.5 ± 1.2 Ferritin (ng/mL) 6.8 ± 9.4 41.2 ± 28.1
The figure reports significant paired increases in Hb and ferritin (p <0.001); the underlying causes were fibroids (52), adenomyosis (23) and dysfunctional uterine bleeding (39). It shows that iron repletion can improve severe anaemia before definitive treatment, but the uncontrolled retrospective cohort does not prove that this exact regimen eliminates transfusion. Choose formulation, total iron dose and route from iron deficit, urgency, tolerance and local protocol. [1][15]
The slide summarises the message as transfusing only haemodynamically unstable patients and using one unit, then reassessing. The safe interpretation is broader: stability is not the sole criterion. Consider haemoglobin, symptoms/signs of inadequate oxygen delivery, active bleeding, rate of fall, cardiovascular disease and the clinical setting. A stable but severely anaemic or symptomatic patient may still require transfusion. [1]
| Clinical Setting | Transfuse When | Target | Source |
|---|---|---|---|
| Most haemodynamically stable hospitalised adults | Consider at Hb < 7 g/dL | If transfused under the NICE restrictive strategy, 7–9 g/dL | [14][15] |
| Stable adults undergoing cardiac surgery | A threshold around 7.5 g/dL may be chosen | Individualise | [14] |
| Orthopaedic surgery or stable pre-existing cardiovascular disease | A threshold around 8 g/dL may be chosen | Individualise | [14] |
| Stable adults with haematological/oncological disorders | Consider at Hb < 7 g/dL; evidence is lower certainty | Individualise disease-specific goals | [14] |
| Acute variceal bleeding (cirrhosis) | Hb < 7 g/dL | 7–9 g/dL (restrictive) | [4][5] |
| Acute MI / ACS with anaemia | Do not apply the 7 g/dL rule automatically. NICE uses 8 g/dL (target 8–10), while the 2025 AABB AMI guideline conditionally favours a liberal strategy when Hb is below 10 g/dL | Apply the current local cardiology/transfusion protocol; balance recurrent ischaemia against heart-failure/TACO risk | [15][16] |
| Major haemorrhage / haemodynamic instability | Activate the local protocol from physiology and bleeding—not a single Hb result | Restore perfusion, oxygen delivery and haemostasis while achieving source control | [7][15] |
| Regular transfusion for chronic anaemia | Individual threshold and target | Disease-specific programme | [15] |
Restrictive vs Liberal Transfusion — Exam Discriminator
Restrictive transfusion (often considering RBCs below Hb 7 g/dL in stable adults) is preferred in many settings. In variceal bleeding specifically, liberal transfusion can increase portal pressure → more rebleeding → worse outcomes [4][5]. This is not a universal trigger: active major bleeding, inadequate oxygen delivery, acute MI, chronic transfusion dependence and important comorbidity require condition-specific guidance. [14][15][16]
Massive Transfusion
The related trauma lecture teaches an initial RBC : FFP : platelet ratio of 1:1:1. Treat this as its example of balanced resuscitation, not a universal prescription: activate the local major-haemorrhage protocol, then use physiology, temperature, ionised calcium, platelet count, coagulation/fibrinogen tests and, where available, viscoelastic testing to guide ongoing component therapy. Single-unit transfusion logic does not apply while haemorrhage is uncontrolled. Definitive management is to stop the bleeding. [7][15]
Complications of massive transfusion (high yield for SAQ):
- Hypothermia — stored blood is cold (2–6°C)
- Hyperkalaemia — K+ leaks out of stored RBCs
- Hypocalcaemia — citrate anticoagulant chelates calcium
- Coagulopathy — dilutional (dilution of clotting factors and platelets) + consumption
- Metabolic alkalosis — citrate is metabolised to bicarbonate
- TACO — volume overload
- Transfusion reactions — increased exposure = increased risk
What If the Patient Refuses Transfusion?
Patients may request no blood transfusion for religious, cultural or personal reasons (perceived infectious risk). [1]
Patients may request autologous blood or directed donation. [1]
- Confirm decision-making capacity and voluntariness, explain material risks/benefits and document the discussion.
- Clarify exactly which components, fractions and techniques the patient accepts; “no blood” is not sufficiently specific for perioperative planning.
- Understand the risks of allogeneic, autologous and directed donation. Directed blood is not inherently safer.
- Explore alternatives and timing—treat anaemia, control bleeding and agree an emergency plan early enough to avoid preventable delay.
Theoretically safer, but: [1]
- Not every patient eligible/suitable
- Risk of bacteraemia
- Risk of mix-up (clerical error still possible)
- Risk of wastage (if not needed, it is discarded — cannot be given to others)
Not every potential donor is eligible/suitable. [1]
- Donor may hide important information or be under pressure to donate
- Risk of positive infectious disease markers → wastage
- Risk of TA-GvHD — because a family member is more likely to share HLA haplotypes → donor lymphocytes are not rejected and attack recipient. Prevented by irradiation. [1]
Directed Donation TA-GvHD Risk
This is a classic exam trap. Students assume directed family donation is safer, but shared HLA haplotypes can permit donor lymphocytes to engraft and cause fatal TA-GvHD. Cellular components from first- or second-degree relatives must be irradiated, even if the recipient is immunocompetent; “all directed donations must be irradiated” is too broad because the indication depends on relationship, component and local policy. [23]
Type and screen (group and screen) [8][22]
- Type: ABO and RhD grouping.
- Screen: test the patient's plasma for clinically significant red-cell antibodies.
- Compatibility testing still occurs: eligible antibody-negative patients may have an electronic or immediate-spin crossmatch; a current/history-positive clinically significant antibody requires antigen-negative units and an antiglobulin crossmatch. “No serological crossmatch” does not mean “no compatibility check”.
| Key Fact | Detail |
|---|---|
| Sample validity | Commonly 72 hours if transfused or pregnant within the preceding 3 months (or if history is uncertain), because new antibodies can appear rapidly. Longer validity may be permitted only under the local laboratory policy. [22] |
| Lecture/senior-note extensions | The “1 week for thalassaemia” and “1 month for operative patients” statements are local-note claims, not universal rules; verify directly with the receiving blood bank. |
| Platelet transfusion | RBC crossmatching is not usually required, but ABO-identical/compatible platelets are preferred when feasible and donor-plasma compatibility remains relevant. |
| Plasma transfusion | Recipient ABO group must be known and plasma must be ABO compatible; an RBC antibody screen is not what makes plasma compatible. |
| Product | When it may be indicated | Guardrail |
|---|---|---|
| Red cells | In a stable adult, commonly consider at Hb <7 g/dL; use higher/individual thresholds for specified settings and symptoms | One unit then clinical/Hb reassessment only if not actively bleeding. Emergency-release group O selection is sex/age and local-policy dependent. [14][15] |
| Platelets | Examples: non-bleeding hypoproliferative thrombocytopenia <10 ×10⁹/L; lumbar puncture <20; major non-neuraxial surgery <50. NICE uses <30 for clinically significant bleeding and up to 100 for severe/critical-site bleeding | Thresholds vary by mechanism, bleeding, procedure and guideline. The slide-era “<20 for fever/sepsis” is not a universal current trigger. Give a single adult dose, then reassess. [15][17] |
| FFP | Clinically significant bleeding with multiple-factor deficiency and abnormal coagulation tests; selected major-haemorrhage/DIC settings | Not a volume expander and not for an isolated mildly abnormal INR in a non-bleeding patient. It is not the preferred agent for vitamin-K-antagonist reversal. [15] |
| Cryoprecipitate | Clinically significant bleeding with fibrinogen <1.5 g/L; prophylaxis before a bleeding-risk procedure may be considered if fibrinogen <1.0 g/L | Dose to fibrinogen deficit and recheck the level; major haemorrhage/obstetrics follow their specific protocol. [15] |
Clinical Case from the Lecture
A 47-year-old woman with severe menorrhagia, Hb 4.0, multiple fibroids, advised for hysterectomy, refused transfusion. [1]
Management in acute stage: [1]
- If she gives informed consent after discussion, transfuse one unit for severe symptoms/physiological compromise, then reassess; do not attempt to normalise chronic anaemia rapidly. If refusal persists, respect it and pursue non-blood measures.
- Replace iron and calculate the deficit. IV iron is reasonable when rapid repletion is needed or oral iron is unsuitable; it is not automatically preferred for every patient. [15]
- Haemostatic drugs (e.g. tranexamic acid) to control excessive bleeding
After stabilisation with iron, menorrhagia persisted. Electively admitted for surgery with Hb ~12. [1]
- Does she need prophylactic transfusion solely because surgery is planned? → No. Hb around 12 g/dL does not justify pre-operative RBC transfusion. Hysterectomy can still cause important blood loss, so quantify procedural risk and agree haemostasis, cell-salvage and emergency plans rather than claiming bleeding is negligible. [1][15]
- If she asks for directed donation? → Not recommended. Risk of TA-GvHD, pressure on donor, potential wastage, positive markers. [1]
Summary points from the lecture: [1]
- Blood transfusion carries benefits but also risks and adverse events
- Blood supply can be limited and has shelf life; many reasons prevent immediate availability
- Use a restrictive, indication-based strategy. In a stable non-bleeding adult, give one unit and reassess rather than ordering multiple units automatically.
- Alternative measures are available—diagnose and treat iron deficiency, minimise blood loss, and use haemostatic strategies. IV iron is selected when oral therapy is unsuitable or too slow; it is not a universal replacement for urgent RBC transfusion.
- Think twice or even more times before initiating a blood transfusion
Integration with Related GC Lectures
This lecture complements GC 155 by covering the acute and chronic complications in detail:
- Acute reactions: FNHTR, allergic, AHTR, septic, TRALI, TACO, anaphylaxis
- Chronic complications: iron overload, delayed haemolytic reaction, infection transmission
- Step 1 of any transfusion reaction: STOP the transfusion, keep IV patent with NS, recheck identity, send blood bag for investigation
- In trauma: early blood transfusion for transient or non-responders
- The lecture's initial RBC:FFP:platelet ratio is 1:1:1; actual component packs and subsequent dosing follow the local major-haemorrhage protocol and laboratory/viscoelastic results
- Vasopressors do not replace blood-volume resuscitation or source control in haemorrhagic shock; if used as a temporary adjunct for refractory hypotension, they must not delay definitive control of bleeding. Steroids are not routine treatment for uncomplicated hypovolaemic shock.
- Restrictive transfusion strategy (Hb < 7, aim 7–9)
- Exception: major bleeding is physiology-driven; stable cardiovascular disease may use a threshold around 8 g/dL, while acute MI/ACS requires its current specific guidance
- In variceal bleeding: liberal transfusion increases portal pressure → rebleeding
Exam Intelligence
| Trap | Correct Answer |
|---|---|
| "Transfuse to normal Hb" | No. Most stable adults use a restrictive, context-dependent strategy; Hb 7 g/dL is a common consideration threshold, not an automatic universal trigger. |
| "O negative blood is always given in emergency" | Prefer group-specific blood as soon as safely available. Emergency group O RhD selection depends on sex, age, inventory and local policy; collect a pre-transfusion sample without delaying life-saving blood. [22] |
| "Directed donation from family is safer" | No. It has the ordinary transfusion risks plus coercion/wastage concerns; cellular components from first- or second-degree relatives require irradiation because of TA-GvHD risk. [23] |
| "Autologous blood has no risk" | Wrong. Risk of bacteraemia, mix-up, wastage. |
| "Platelet transfusion needs an RBC cross-match" | Usually no, but ABO-identical/compatible platelets are preferred and local plasma-compatibility rules still apply. |
| "FFP doesn't need compatibility testing" | Wrong. Plasma must be ABO compatible; do not confuse this with the RBC antibody screen/crossmatch. |
| "Transfuse more blood in variceal bleeding" | No. Liberal transfusion increases portal pressure → rebleeding → worse survival. Use restrictive strategy. |
| "The lecture's viral-risk numbers are current" | No. The public BTS estimates use 2016/17 epidemiology; among HIV/HCV/HBV, the published estimate is highest for HBV. [19] |
| "More units = better outcome" | Wrong. In a non-bleeding adult, give one RBC unit and reassess. Active major haemorrhage follows its protocol. |
- Restrictive transfusion strategy is the default for many haemodynamically stable adults, but the threshold must be adjusted for symptoms, ongoing bleeding and myocardial ischaemia.
- A patient with IHD + upper GI bleeding + Hb 7.5 g/dL cannot be managed from the number alone: assess stability, active bleeding, symptoms and ischaemia, then apply the relevant local guideline.
- In the past-paper stems, “restrictive strategy” means avoiding reflexive liberal/multi-unit correction; it does not mean that no RBC unit can be given at Hb 7.5 g/dL when cardiovascular disease, symptoms or ongoing bleeding justify it.
High Yield Summary
-
Blood transfusion is NOT always needed
- alternatives include cause-directed anaemia treatment, haemostatic drugs, cell salvage and broader PBM.
-
4 Dimensions
- Adequacy (supply is limited), Quality, Safety (blood is never 100% safe), Outcome (balance risks vs benefits).
-
Restrictive transfusion strategy
- In most stable adults, consider RBC transfusion below Hb 7 g/dL. Cardiac surgery, orthopaedics/pre-existing CVD, acute MI/ACS, chronic transfusion and major haemorrhage require different or individualised approaches.
-
Single Unit Transfusion
- In a non-bleeding adult, give one RBC unit and reassess. This does not apply to uncontrolled major haemorrhage.
-
Residual-risk figures are historical estimates
- BTS's public figures use 2016/17 donor data: HIV about 1 in 3.4 million, HCV less than 1 in 10 million and HBV about 1 in 126,000. [19]
-
Non-infectious risks are far more common
- FNHTR, allergic reactions, TACO (often under-recognised), TRALI, haemolytic reaction.
-
Patient Blood Management
- is a WHO-endorsed patient-centred framework. The Western Australia study associated implementation with reduced component use and improved outcomes but cannot prove every reduction was caused by PBM.
-
Directed donation carries risk of TA-GvHD
- cellular components from first- or second-degree relatives require irradiation. Autologous blood still carries collection, bacterial contamination, mix-up and wastage risks.
-
Massive transfusion complications
- hypothermia, hyperkalaemia, hypocalcaemia, dilutional coagulopathy, metabolic alkalosis.
-
T/S validity: 72 hours
- applies commonly after recent transfusion/pregnancy or uncertain history; otherwise follow local blood-bank validity rules. Platelets do not usually need an RBC crossmatch; plasma must be ABO compatible.
- Treat iron deficiency with the appropriate route
- oral iron is generally first-line when tolerated and time permits; IV iron is useful when oral therapy is unsuitable or too slow. The lecture's local cohort improved Hb from 7.1 to 10.5 g/dL after IV iron sucrose plus oral iron.
Active Recall - Blood Transfusion in Patient Management
[1] Lecture slides: GC 155. Is blood transfusion absolutely required in patient management nowadays.pdf [2] Senior notes: Maksim Medicine Notes.pdf (Haematology section, pp. 181–184) [3] Senior notes: Ryan Ho Haemtology.pdf (Section 5.1 Transfusion Medicine) [4] Senior notes: Block A - Abdominal distension_ ascites and cirrhosis.pdf (Restrictive transfusion in variceal bleeding) [5] Senior notes: Block A - Coffee ground vomitus tarry stool upper GI bleeding.pdf (Restrictive transfusion exceptions) [6] Senior notes: MBBS Final MB (Surgery) (Felix PY Lai).pdf (Transfusion thresholds in UGI bleeding) [7] Lecture slides: GC 188. Hit by a van, in shock with internal bleeding Abdominal injury.pdf (pp. 25, 31) [8] Senior notes: Block A - Introduction to Haematological investigations (CBP, Clotting).pdf (Part 3: Transfusion) [9] Lecture slides: GC 049. Fever after a blood transfusion.pdf [14] Carson JL, Stanworth SJ, Guyatt G, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA. 2023;330:1892–1902. [15] NICE. Blood transfusion (NG24). Published 2015; updated 26 February 2026. [16] Pagano MB, Stanworth SJ, Dennis J, et al. Red Cell Transfusion in Acute Myocardial Infarction: AABB International Clinical Practice Guidelines. Ann Intern Med. 2025;178:1469–1477. [17] Metcalf RA, Nahirniak S, Guyatt G, et al. Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines. JAMA. 2025;334:606–617. [18] World Health Organization. The urgent need to implement patient blood management: policy brief. 2021. [19] Hong Kong Red Cross Blood Transfusion Service. Infectious Disease Testing (public residual-risk estimates use 2016/17 donor data). [20] Hong Kong Red Cross Blood Transfusion Service. Blood Processing (component testing, storage and shelf life). [21] Australian Red Cross Lifeblood. Management of suspected transfusion reactions and TACO. Updated 2026. [22] Australian Red Cross Lifeblood. Pretransfusion specimen collection and compatibility testing. Updated January 2026. [23] British Society for Haematology. Guidelines on the use of irradiated blood components. 2020; reviewed 2021.
GC154 Biochemical Screening For Early Detection Of Diseases
Biochemical screening for early detection of diseases involves the systematic use of laboratory tests—such as blood glucose, lipid profiles, newborn metabolic panels, and tumor markers—to identify presymptomatic or early-stage conditions in apparently healthy individuals, enabling timely intervention and improved outcomes.
GC156 Many Of My Family Members Have Cancers Cancer Genetics And Cytogenetics (file 1)
Cancer genetics and cytogenetics is the study of hereditary gene mutations and chromosomal abnormalities that predispose individuals and their families to the development of various malignancies.